Targeted Genetics Regains Momentum Following Clinical Trial Hold For Biologic
This article was originally published in The Pink Sheet Daily
Executive Summary
Seattle-based firm presents data suggesting supplemental therapeutic tgAAC94 did not contribute to subject’s death during clinical trial.
You may also be interested in...
Targeted Genetics Aims To Reinitiate Arthritis Gene Therapy Trial By December
Data reviewed by NIH Recombinant DNA Advisory Committee suggest it is unlikely the experimental therapy contributed to a patient’s death in July, CEO says.
Targeted Genetics To Examine Safety of Recombinant AAV Technology Following Patient Death
Biotech firm halts Phase I/II trials of inflammatory arthritis therapy.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?